Type: full-replacement policy counterplan in the public option family. Everything true of the public option counterplan is true here, including the competition problem. Read that essay alongside this one.
Wording the Counterplan
A Medicare-administered plan available to everyone, improved employer-based coverage, enhanced Medicaid, and an optional plank for direct cost control.
The branding matters more than it should. “Part E” positions the counterplan as an extension of an existing popular program rather than a new government insurer, which is worth something in the solvency debate — Medicare familiarity, existing administrative infrastructure, established provider networks — and in the politics debate.
The optional cost-control plank is a real choice. Read it when you need to solve a cost advantage; leave it out when you are worried about rate-setting disadvantages, because it is the plank that triggers them and the plank that triggers the pharma link.
Competition
Definitional, and it is borrowed from the public option counterplan file: single payer replaces private health insurance plans, and this counterplan preserves them. Mutually exclusive because the plan eliminates private insurance while the counterplan preserves choice and competition.
That argument decides whether the counterplan competes at all. If a Medicare-administered universal plan counts as national health insurance, the affirmative permutes and you are done.
And the argument binds your squad. Michigan’s public option counterplan file argues the public option is not national health insurance because it sits under the Bismarck model. If that is right, this counterplan competes — and the public option affirmative in the same file set is untopical. Somebody with all these files will notice.
Net Benefits
Taxes. The counterplan achieves near-universal coverage without single payer’s tax increase, and the solvency evidence claims 99.6 percent coverage at lower cost with permanent administrative savings.
Do not run pharma as the net benefit without resolving a contradiction. CNDI’s public option counterplan claims to avoid the pharma disadvantage; Michigan’s own public option negative file has two cards saying pharma innovation gets decked by a public option. Part E with the cost-control plank sets prices, which is what the pharma literature is about.
Answering the Permutation
Perm do both gets the mutual-exclusivity answer — the plan eliminates private insurance, the counterplan preserves it, and both cannot happen. Then extend the tax net benefit, which survives the permutation because the permutation includes single payer’s financing.
Perm do the counterplan gets the severance answer: single payer replaces private plans, so an affirmative advocating a system that preserves them has abandoned its own mandate.
The permutation the file hands the affirmative: perm do the counterplan and let it evolve. The solvency section argues the counterplan can evolve into something close to single payer if it outcompetes the private market — which is a fine solvency card and a disastrous competition card. The affirmative reads it to argue the counterplan is either not competitive or not different, and reads it again to argue the counterplan’s own advocates think single payer is the endpoint.
Do not read the evolution card and the competition block in the same speech. Pick one.
For the affirmative: the evolution card is your best perm evidence and it is in their file.
